Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses, CMS-4180-P

NOF on behalf of the NBHPI has submitted comments to CMS and HHS regarding proposed rules that could impact osteoporosis patients access to testing and treatment. The following comment letter was submitted on January 25, 2019:

Dear Administrator Verma:

The National Osteoporosis Foundation (NOF) is pleased to submit its comments to the above- referenced proposed rule entitled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses (the Proposed Rule). We previously responded to the Centers for Medicare & Medicaid Services’ (CMS’) International Pricing Index Model (IPI) proposal for Part B drugs, noting our significant concerns that it could have an unintended consequence of exacerbating real-world deficiencies in osteoporosis care for Medicare beneficiaries. This Proposed Rule raises similar concerns and, when layered onto a potential IPI Model, places CMS’ policy initiatives at increasing odds with its “patients first” promise to our nation’s elderly and disabled populations.

Click here to read the full letter.